Investor Presentation Q1 2023

62 Investor presentation First three months of 2023 In STEP 5, people treated with semaglutide 2.4 mg sustained their weight loss over 2 years Clinically relevant and sustained weight loss in patients % change in body weight 0 with obesity or overweight Placebo: -0.6% Data from STEP 5 -6 2 46 ∞ -2 -4 -8 -10 -12 -14 -16 -18 -20 Semaglutide 2.4 mg: -16.7% 08 16 24 32 40 48 56 64 72 80 88 96 104 Time since initiation (weeks) Change in body weight in % depicts observed means since time of randomisation; trial product estimand; mean body weight: 106.0 kg M 40% of patients lost ≥ 20% of their body weight Semaglutide appeared to have a safe and well-tolerated profile Novo NordiskⓇ Improvements in lipid profiles as well as C- reactive protein

View entire presentation